Journal article
Down syndrome preleukemia and leukemia.
- Abstract:
- Children with Down syndrome (DS) and acute leukemias acute have unique biological, cytogenetic, and intrinsic factors that affect their treatment and outcome. Myeloid leukemia of Down syndrome (ML-DS) is associated with high event-free survival (EFS) rates and frequently preceded by a preleukemia condition, the transient abnormal hematopoiesis (TAM) present at birth. For acute lymphoblastic leukemia (ALL), their EFS and overall survival are poorer than non-DS ALL, it is important to enroll them on therapeutic trials, including relapse trials; investigate new agents that could potentially improve their leukemia-free survival; and strive to maximize the supportive care these patients need.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 627.9KB, Terms of use)
-
- Publisher copy:
- 10.1016/j.pcl.2014.09.009
Authors
- Publisher:
- Elsevier
- Journal:
- Pediatric Clinics of North America More from this journal
- Volume:
- 62
- Issue:
- 1
- Pages:
- 121-137
- Publication date:
- 2014-11-28
- DOI:
- EISSN:
-
1557-8240
- ISSN:
-
0031-3955
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:493463
- UUID:
-
uuid:f2ce4a84-b6f2-403c-ae90-bfbc7e3e4edb
- Local pid:
-
pubs:493463
- Source identifiers:
-
493463
- Deposit date:
-
2015-01-06
- ARK identifier:
Terms of use
- Copyright holder:
- Elsevier Inc
- Copyright date:
- 2014
- Notes:
- Copyright © 2015 Elsevier Inc. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.pcl.2014.09.009
If you are the owner of this record, you can report an update to it here: Report update to this record